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Abstract
Background: The Japanese Respiratory Society guidelines propose a differential diagnosis for
atypical pneumonia and bacterial pneumonia using a scoring system for the selection of appropriate
antibiotic. In order to improve this scoring system, the guidelines are seeking new specific
parameter. The purpose of this study was to clarify the pattern of abnormalities with Mycoplasma
pneumoniae  pneumonia on chest computed tomography (CT) and whether the radiographic
findings could distinguish M. pneumoniae pneumonia from Streptococcus pneumoniae pneumonia.
Methods: A retrospective review was performed of the CT findings of 64 cases and 68 cases
where M. pneumoniae and S. pneumoniae, respectively, were the only pathogen identified by the
panel of diagnostic tests used.
Results:  Of the 64 patients with M. pneumoniae pneumonia, bronchial wall thickening was
observed most frequently (81%), followed by centrilobular nodules (78%), ground-glass attenuation
(78%), and consolidation (61%). Bronchial wall thickening and centrilobular nodules were observed
more often in M. pneumoniae patients than in S. pneumoniae patients (p < 0.0001). The presence of
bilateral bronchial wall thickening or centrilobular nodules was only seen in patients with M.
pneumoniae pneumonia. Using the scoring system of the Japanese Respiratory Society guidelines
and chest CT findings, 97% of M. pneumoniae patients were suspected to be M. pneumoniae
pneumonia without serology. When comparing the CT findings between early stage and
progressed stage in the same patients with severe pneumonia, the radiographic features of early
stage M. pneumoniae pneumonia were not observed clearly in the progressed stage.
Conclusion: The present results indicate that the diagnosis of M. pneumoniae pneumonia would
appear to be reliable when found with a combination of bronchial wall thickening and centrilobular
nodules in the CT findings. However, these CT findings are not observed in progressed severe M.
pneumoniae pneumonia patients.
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Background
Community-acquired pneumonia (CAP) is a common
infection, which is sometimes fatal. Despite substantial
progress in therapeutic options, CAP remains a significant
cause of morbidity and death worldwide (the fourth lead-
ing cause of death in Japan). Mycoplasma pneumoniae is
one of the most frequent causes of respiratory tract infec-
tions, accounting for as many as 10–30% of all cases of
CAP [1-3]. Epidemiological studies in Japan have demon-
strated that the incidence of M. pneumoniae pneumonia is
the second leading pathogen of CAP next to Streptococcus
pneumoniae [3,4]. Serological testing is currently the most
common tool for the diagnosis of M. pneumoniae infec-
tion. However, this test requires paired serum samples
with a two to four week interval and provides only a ret-
rospective diagnosis.
The etiological matter that most clearly differentiates Asia
from Western countries is the frequency of drug-resistant
S. pneumoniae, and especially the high-level of macrolide-
resistant  S. pneumoniae [5-7]. Approximately half of S.
pneumoniae  cases show strong resistance to macrolides
with minimum inhibitory concentrations greater than or
equal to 128 μg/mL [5,7]. Therefore, it is difficult to man-
age both bacterial and atypical pneumonias by medica-
tion with macrolide antibiotics as the first-choice drug. In
addition, in recent years the incidence of fluoroqui-
nolone-resistant  S. pneumoniae has risen markedly and
particularly in patients over 60 years of age [7,8]. Further-
more, fluoroquinolone-resistant Haemophilus influenzae
has also emerged [7,9]. Therefore, the usage of fluoroqui-
nolones as an empirical first choice drug should be lim-
ited to only selected patients who have co-morbid
illnesses, are of an older age group, have used antibiotics
recently, or have severe CAP to prevent an increase in the
frequency of quinoline-resistant strains [4].
These facts indicate that it could be important to distin-
guish atypical pneumonia, especially M. pneumoniae
pneumonia, from S. pneumoniae pneumonia for the
empirical selection of antibacterial therapy. Thus, the Jap-
anese Respiratory Society (JRS) CAP guidelines are on trial
to differentiate between atypical pneumonia and bacterial
pneumonia using a scoring system [4]. The guidelines
have six parameters and criteria based on clinical features
of M. pneumoniae pneumonia [10]. However, using this
system there are still many cases where the guidelines can-
not differentiate between M. pneumoniae pneumonia and
S. pneumoniae pneumonia, and the JRS guidelines are
seeking new specific parameters in order to improve this
scoring system [4]. Some reports have focused on radio-
graphic features using high-resolution computed tomog-
raphy (HRCT) of M. pneumoniae pneumonia [11-15].
However, to our knowledge, there have been relatively
few comparative studies that have investigated the radio-
graphic findings of M. pneumoniae pneumonia versus S.
pneumoniae pneumonia. The purpose of this study was to
clarify the pattern of abnormalities with M. pneumoniae
pneumonia on chest CT and whether the radiographic
findings could distinguish M. pneumoniae pneumonia
from S. pneumoniae pneumonia. Furthermore, this study
also evaluated the performance of CT scans take at differ-
ent stages of infection.
Methods
Study population
The study was retrospective and included adult patients
with CAP who underwent HRCT. In all patients, CT
images were obtained before treatment with antibiotics.
Patients were seen at Kurashiki Daiichi Hospital, Kawa-
saki Medical School Kawasaki Hospital, and Kawasaki
Medical School Hospital, Okayama, Japan, between April
2000 and December 2008. None of the patients were
immunocompromised; namely patients with HIV infec-
tion, neutropenia secondary to chemotherapy, or patients
on immunosuppressants; or patients with history of
chronic lung diseases, from nursing homes, or patients
with recent (<30 days) admission to hospital. The diagno-
sis was based on clinical signs and symptoms (cough,
fever, productive sputum, dyspnea, chest pain, or abnor-
mal breath sounds), and radiographic pulmonary abnor-
malities that were at least segmental and were not due to
pre-existing or other known causes. All cases of pneumo-
nia occurring more than three days after hospitalization
were considered nosocomial and were excluded. The
study protocol was approved by the Ethics Committee at
Kawasaki Medical School.
Microbiological laboratory tests
Microbiological tests such as Gram stain, cultures, urinary
antigen tests, and serological tests were performed as
described previously [3,16]. Blood cultures and nasopha-
ryngeal swab specimens were obtained from all patients
on admission and, if pleural fluid and sputum were avail-
able, a Gram stain test and a quantitative culture were
obtained. Sputum data were only evaluated when the
Gram stain test revealed numerous leukocytes (>25 in a ×
100 microscopic field) and few squamous epithelial cells
(<10 in a × 100 microscopic field). Certain invasive meth-
ods such as bronchoscopic examination were employed
to obtain specimens in some patients after full explana-
tion of the procedures. These specimens were also used for
culturing of M. pneumoniae and Legionella species on pleu-
ropneumonia-like organism broth and agar (70% pleu-
ropneumonia-like organism broth [Difco, Inc., Detroit,
MI, USA] supplemented with 20% heat-inactivated horse
serum, 10% fresh yeast extract [25%], thallium acetate
[final concentration 0.5 mg/mL], and sterile penicillin G
[final concentration 1,000 U/mL]) and buffered charcoal-
yeast extract alpha agar, respectively. Cultures for Chlamy-BMC Medical Imaging 2009, 9:7 http://www.biomedcentral.com/1471-2342/9/7
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dophila pneumoniae and C. psittaci were performed using
cycloheximide-treated HEp-2 cells grown in a 24-well cell
culture plate [16]. All specimens were passed twice. Cul-
ture confirmation was done by fluorescent-antibody
staining with C. pneumoniae and C. psittaci species-specific
and genus-specific monoclonal antibodies. Broncho-
scopic specimens were also used for polymerase chain
reaction (PCR) of M. pneumoniae and chlamydial species.
The M. pneumoniae-specific primers used for the PCR were
from the DNA base sequence within the P1 cytadhesin
gene, and amplification was performed as reported by
Ramirez et al. [17]. The C. pneumoniae-specific and genus-
specific primers used for PCR were from the DNA base
sequence within the 53-kDa protein gene and major outer
membrane protein gene, respectively, established in our
laboratory. These assays were performed as described pre-
viously [3,18].
Paired serum samples were collected at intervals of at least
four weeks after onset. Complement fixation tests were
done in all patients for antibodies to influenza A and B
viruses, adenovirus, respiratory syncytial virus, cytomega-
lovirus, and parainfluenza virus types 1, 2, and 3. Anti-
bodies to M. pneumoniae were measured by a passive
agglutination test (Serodia-Myco II kit, Fujirebio, Tokyo,
Japan),  Legionella  species by a microagglutination test
(detection of L. pneumophila serogroups 1~6, L. bozoema-
nii, L. dumoffii, L. gormanii, and L. micdadei), and Coxiella
burnetii by an indirect immunofluorescence test. A micro-
immunofluorescence test was used for the titration of IgG
and IgM antibodies against chlamydial species, using for-
malinized elementary bodies of C. pneumoniae KKpn-15,
C. trachomatis L2/434/Bu, and C. psittaci Budgerigar-1
strains as antigens [16]. Rheumatoid factors were
absorbed with GullSORB (Meridian Bioscience Inc., OH,
USA) before IgM titrations. In addition to serology, cultur-
ing, and/or PCR, a urinary antigen test (Binax NOW,
Binax Inc. Portland, ME, USA) was used for the detection
of S. pneumoniae and L. pneumophila.
Criteria for the determination of microbial etiology
Microbial etiology was classified as "definitive", "pre-
sumptive", or "unknown" as reported previously [3]. Bac-
teria were considered to be definitive causative agents
when isolated from blood or pleural fluid cultures. The
results of sputum cultures were considered in combina-
tion with Gram stain findings. An organism showing
heavy (≥ 107 cfu/mL) or moderate (106 cfu/mL) growth of
a predominant bacterium on a sputum culture was con-
sidered to be a presumptive pathogen. Any microorgan-
ism isolated from bronchoscopic specimens was
considered to be a presumptive pathogen when its con-
centration reached >105 cfu/mL in quantitative culture. If
M. pneumoniae or Legionella species were isolated from a
specimen, that specimen was considered to be a definitive
pathogen even if the culture showed little growth. L. pneu-
mophila  and  S. pneumoniae were considered to be pre-
sumptive agents when the urinary antigen test was
positive. For serological tests, a four-fold rise in the anti-
body titer level between paired sera was considered defin-
itive. Acute C. pneumoniae or  C. psittaci infection was
defined as IgM ≥ 1:32 or a four-fold rise in IgG or IgM titer
between acute and convalescent serum samples.
Chest CT findings
CT examinations were performed using a Hi-Speed
Advantage scanner (General Electric Medical Systems,
Milwaukee, WI, USA), Hi-Speed LX/i Advantage (General
Electric Medical Systems), or a Light Speed Ultra (General
Electric Medical Systems). All scans were obtained during
suspended end inspiration with the patient in a spine
position. HRCT was performed with 1-mm collimation at
10-mm intervals. Images were obtained at lung (level -700
HU; width, 1,500 HU) and mediastinal (level 20–40 HU;
width, 400 HU) levels. The time between clinical onset of
pneumonia (fever and/or respiratory symptoms) and CT
ranged from 1 to 10 days (mean, 5.1 days) for M. pneumo-
niae pneumonia and from 1 to 12 days (mean, 5.2 days)
for S. pneumoniae pneumonia. Contrast material was used
in 12 patients with M. pneumoniae or S. pneumoniae pneu-
monia.
Three chest radiologists (16, 12 and 10 years experience,
respectively), who were blinded to the diagnoses, retro-
spectively and independently assessed the presence of
consolidation, ground-glass attenuation, centrilobular
nodules, thickening of the bronchial wall, reticular or lin-
ear opacity, pleural effusion, and lymphadenopathy.
Readers also evaluated if the pneumonia was unilateral or
bilateral and identified the opacity pattern of pneumonia.
In addition, it was recorded which lobe of the lung was
involved.
Consolidation was defined as air-space opacification with
obscuration of the underlying vasculature. Ground-glass
attenuation was defined as mildly increased attenuation
without obscuration of the underlying vasculature. A cen-
trilobular nodule was defined as a nodule identified
around the peripheral pulmonary arterial branches or 3 to
5 mm away from the pleura, interlobular septa, or pulmo-
nary veins. Bronchial wall thickening was defined as the
thickening identified widespread areas not close to areas
of ground-glass attenuation and/or consolidation. Inter-
lobular septa thickening, intralobular interstitial thicken-
ing, and areas of irregular linear opacity were all classified
as reticular or linear opacity. The reticular framework in
ground-glass attenuation that is described as crazy-paving
appearance was not classified as an area of reticular or lin-
ear opacity. Mediastinal lymphadenopathy was judged to
be present when the minimal diameter of a lymph nodeBMC Medical Imaging 2009, 9:7 http://www.biomedcentral.com/1471-2342/9/7
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was larger than 10 mm. Hilar lymphadenopathy was
judged to be present only if the maximum diameter of the
ipsilateral hilum exceeded that of the contralateral hilum
by 1.5-fold or more. The final decisions for the presence
of each finding and the opacity pattern for each case were
reached by the consensus of the three radiologists.
Differential diagnosis in JRS guidelines
The JRS guidelines include six parameters and criteria
based on underlying conditions, clinical symptoms, and
laboratory findings by multiple regression analysis [10].
These parameters are; 1) under 60 years of age, 2) no or
minor co-morbid illness, 3) the patient has stubborn
cough, 4) the patient has poor chest auscultatory findings,
5) no sputum or identified etiological agent by rapid diag-
nostic tests, and 6) a peripheral white blood cell (WBC)
count below 10,000/mm3. When there is a correlation of
more than four parameters out of six, then the guidelines
recommend the use of macrolides or tetracyclines for sus-
pected M. pneumoniae pneumonia [4]. If these criteria are
not met, the guidelines recommend the use of β-lactams
for suspected S. pneumoniae pneumonia [4].
Statistical analysis
Statistical analysis was performed using Stat View version
5.0. (SAS Institute Inc, Cary, NC, USA). The incidence of
underlying conditions, clinical findings, and radiographic
findings were analyzed using Fisher's Exact test. Mean age
of patients and laboratory data were compared using Stu-
dent's t test. For each radiological finding, kappa values
were calculated between the readers.
Results
Five hundred and sixty-five patients were enrolled in this
study. A microbiological diagnosis was established in 298
patients. Among all CAP cases, there were 64 cases and 68
cases where M. pneumoniae and  S. pneumoniae, respec-
tively, was the only pathogen identified by the panel of
diagnostic tests used. Cases of pneumonia mixed with
other microorganisms were excluded in this study. All M.
pneumoniae cases demonstrated four-fold antibody sero-
conversion (10 cases were culture positive).
Table 1 shows the clinical characteristics of pneumonia
patients on admission to hospital. The mean age of the
patients with M. pneumoniae pneumonia was significantly
lower than that of those with S. pneumoniae pneumonia (p
< 0.0001). The frequency of a co-morbid illness with M.
pneumoniae pneumonia was significantly lower than with
S. pneumoniae pneumonia (p < 0.0001). The most com-
mon co-morbid illness was diabetes mellitus (M. pneumo-
niae 6, S. pneumoniae 10), followed by cardiovasucular
diseases (M. pneumoniae 3, S. pneumoniae 7), chronic liver
disease (M. pneumoniae 3, S. pneumoniae 6), and cerebrov-
ascular diseases (M. pneumoniae 1, S. pneumoniae 5). The
mean WBC count on admission was significantly lower in
patients with S. pneumoniae pneumonia (p  < 0.0001).
These results were almost identical to the findings of pre-
vious studies [16,19].
The kappa value between the readers was 0.607 for con-
solidation, 0.552 for ground-glass attenuation, 0.746 for
centrilobular nodules, 0.564 for thickening of the bron-
chial wall, 0.587 for reticular or linear opacity, 0.882 for
pleural effusion, and 0.618 for lymphadenopathy. These
values indicated fair to good interreader agreement.
Chest CT findings of the patients with M. pneumoniae
pneumonia and S. pneumoniae pneumonia are listed in
Table 2. Of the 64 patients with M. pneumoniae pneumo-
nia, bronchial wall thickening was observed most fre-
quently (81%), followed by centrilobular nodules (78%),
ground-glass attenuation (78%), and consolidation
(61%) (Figures 1 and 2). Reticular or linear opacities,
pleural effusion, and lymphadenopathy were also
observed, but at low frequencies. Among the CT findings,
bronchial wall thickening and centrilobular nodules were
observed more often in M. pneumoniae patients than in S.
pneumoniae patients (p < 0.0001). Air-space consolidation
was often seen in both pneumonias but as a non-specific
finding (p = 0.0618) (Figure 3). Bronchial wall thickening
or centrilobular nodules, which were considered to be a
spectrum of HRCT findings for bronchopneumonia, were
seen in 59 (92%) patients with M. pneumoniae pneumo-
nia, and in 20 (29%) patients with S. pneumoniae pneu-
monia, which was a statistically significant difference (p <
0.0001). The presence of bilateral bronchial wall thicken-
ing or centrilobular nodules was only seen in patients
with M. pneumoniae pneumonia.
The frequency of involvement in each lobe was not statis-
tically different between patients with M. pneumoniae
pneumonia and S. pneumoniae pneumonia (Table 3).
Table 1: Clinical characteristics in patients with Mycoplasma 
pneumoniae pneumonia and Streptococcus pneumoniae 
pneumonia on admission*
Characteristics M. pneumoniae S. pneumoniae p value
Number 64 68
Mean age (range), years 36.6 (18–69) 61.8 (19–86) <0.0001
Male: Female 34: 30 42: 26 0.3791
Co-morbid illness 15 (23) 33 (48) <0.0001
PSI risk classes**
I – III 41 (64) 29 (43) 0.0154
IV 23 (36) 39 (57)
V0 0
WBC mean (/μL) 7,400 13,800 <0.0001
*Data represent the numbers of patients, and numbers in parentheses 
are percentages.
**PSI, pneumonia severity index.BMC Medical Imaging 2009, 9:7 http://www.biomedcentral.com/1471-2342/9/7
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However, the frequency of involvement of more than one
lobe was seen more often in patients with M. pneumoniae
pneumonia than in patients with S. pneumoniae pneumo-
nia (p = 0.0005).
Using the scoring system of the JRS guidelines, 12 of 64
patients with M. pneumoniae pneumonia were judged as
bacterial pneumonia and 10 of 68 patients with S. pneu-
moniae pneumonia were judged as atypical pneumonia.
Of the 12 patients with M. pneumoniae pneumonia who
were judged as having bacterial pneumonia, 10 patients
showed the radiographic features of M. pneumoniae pneu-
monia with the combination of bronchial wall thickening
and centrilobular nodules. In contrast, 10 patients with S.
30-year-old woman with M. pneumoniae pneumonia Figure 1
30-year-old woman with M. pneumoniae pneumonia. 
CT shows bronchial wall thickening (arrows). Lobular areas 
of consolidation and ground-glass attenuation are also seen.
24-year-old man with M. pneumoniae pneumonia Figure 2
24-year-old man with M. pneumoniae pneumonia. CT 
shows centrilobular nodules (tree-in-bud appearance, 
arrows). Bronchial wall thickening is also seen.
39-year-old man with S. pneumoniae pneumonia Figure 3
39-year-old man with S. pneumoniae pneumonia. CT 
shows air-space consolidation in left lower lobe.
Table 2: Chest CT findings of the patients with Mycoplasma 
pneumoniae pneumonia and Streptococcus pneumoniae 
pneumonia on admission*
Findings M. pneumoniae
(n = 64)
S. pneumoniae
(n = 68)
p value
Consolidation 39 (61) 52 (76) 0.0618
Ground-glass attenuation 50 (78) 32 (47) 0.0003
Centrilobular nodules 50 (78) 15 (22) <0.0001
Bronchial wall thickening 52 (81) 13 (19) <0.0001
Reticular or linear opacity 17 (27) 22 (32) 0.5675
Pleural effusion 13 (20) 17 (25) 0.5409
Lymphadenopathy 15 (23) 13 (19) 0.6707
* Data represent the numbers of patients and numbers in parentheses 
are percentages.BMC Medical Imaging 2009, 9:7 http://www.biomedcentral.com/1471-2342/9/7
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pneumoniae  pneumonia who were judged as atypical
pneumonia did not show the radiographic features of M.
pneumoniae pneumonia.
During the study period, five of 64 patients with M. pneu-
moniae  pneumonia progressed severe pneumonia with
respiratory failure requiring mechanical ventilation (pro-
gressed stage). In these five patients, chest CT was per-
formed in both the non-progressed (mild to moderate
severity pneumonia without respiratory failure) and the
progressed stage. The time between clinical onset of pneu-
monia (fever and/or respiratory symptoms) and CT (pro-
gressed stage) ranged from 8 to 15 days (mean, 10.9
days). All five patients showed the radiographic features
of  M. pneumoniae pneumonia, such as bronchial wall
thickening and centrilobular nodules on admission.
However, at the progressed stage these patients showed
bilateral diffuse infiltrates and did not show the radio-
graphic features of M. pneumoniae pneumonia that was
observed in the non-progressed stage (Figure 4). There
were no any differences in terms of clinical characteristics
on admission between the five patients with progressed
severe pneumonia and the remaining patients.
Discussion
One of the basic policies and main purposes of the JRS
CAP guidelines include the prevention of bacterial resist-
ance because of the high frequency of drug-resistant respi-
ratory pathogens among Asian countries [4]. As shown in
Table 1, there are many clinical differences between M.
pneumoniae pneumonia and S. pneumoniae pneumonia.
These results were similar to those described in previous
reports [16,19]. Thus, the JRS guidelines propose a differ-
ential diagnosis for atypical pneumonia, especially M.
pneumoniae pneumonia, and bacterial pneumonia, pre-
dominantly S. pneumoniae pneumonia, for the selection of
appropriate antibiotic management of CAP [4]. Usually,
chest radiography is the first imaging technique obtained
for the evaluation of acute respiratory symptoms. How-
ever, the patterns of presentation of M. pneumoniae pneu-
monia on chest radiography are nonspecific, consisting of
patchy areas of airspace consolidation, reticular intersti-
tial infiltrates, or both [10,19]. Thus, the JRS guidelines
excluded chest radiographic findings from a differential
table when the guidelines were updated [4]. In contrast,
CT images can more accurately provide detailed informa-
tion about the lung parenchyma than routine chest radi-
ography. Reittner et al. compared the radiographic and
chest CT findings of M. pneumoniae pneumonia and con-
cluded that the lobular distribution, centrilobular
involvement, and interstitial abnormalities in M. pneumo-
niae pneumonia are often difficult to recognize on radio-
graphs but these features can usually be seen on CT [20].
In this study, the CT findings of M. pneumoniae pneumo-
nia were evaluated and compared it with S. pneumoniae
pneumonia, which is the leading pathogen of CAP world-
wide. The most important differences between M. pneumo-
niae and S. pneumoniae pneumonias were the frequency of
bronchial wall thickening and centrilobular nodules.
These findings were observed more often in M. pneumo-
Table 3: Frequency of lobe involvement*
Parameter M. pneumoniae
(n = 64)
S. pneumoniae
(n = 68)
p value
Lobe
Upper 33 (55) 30 (44) 0.2960
Middle 31 (48) 22 (32) 0.0759
Lower 51 (80) 47 (69) 0.2319
More than one lobe involved 46 (72) 31 (47) 0.0005
* Data represent numbers of patients and numbers in parentheses are percentages.
31-year-old man with severe M. pneumoniae pneumonia with  respiratory failure requiring mechanical ventilation Figure 4
31-year-old man with severe M. pneumoniae pneu-
monia with respiratory failure requiring mechanical 
ventilation. CT shows bilateral air-space consolidation and 
pleural effusion.BMC Medical Imaging 2009, 9:7 http://www.biomedcentral.com/1471-2342/9/7
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niae patients than in S. pneumoniae patients (p < 0.0001).
Furthermore, the presence of bilateral bronchial wall
thickening or centrilobular nodules may be highly sugges-
tive for M. pneumoniae pneumonia. Nambu et al. reported
that the difference in frequency of bronchovascular bun-
dle thickening (bronchial wall thickening) and peribron-
chovascular or centrilobular nodules between M.
pneumoniae and S. pneumoniae was statistically significant
(p = 0.004) [15]. Air-space consolidation with or without
centrilobular or peribronchovascular nodules were often
seen in both pneumonias and were nonspecific. Reittner
et al. also reported that centrilobular nodules were
detected more frequently in M. pneumoniae pneumonia
(86%) than in bacterial pneumonias (17%, p < 0.01) [20].
The finding of bronchial wall thickening was not evalu-
ated in that study. These data together with the present
results suggest that M. pneumoniae pneumonia may be dif-
ferentiated from S. pneumoniae pneumonia using CT find-
ings with the combination of bronchial wall thickening
and centrilobular nodules.
To confirm whether CT findings can differentiate M. pneu-
moniae  pneumonia from S. pneumoniae pneumonia,
patients with M. pneumoniae pneumonia who were sus-
pected as having bacterial pneumonia were evaluated by
the scoring system of the JRS guidelines. Of these, 83%
patients could be differentiated from S. pneumoniae pneu-
monia by radiographic features. In contrast, all patients
with S. pneumoniae pneumonia who were suspected as
atypical pneumonia did not show the radiographic fea-
tures of M. pneumoniae pneumonia. Thus, the diagnosis of
M. pneumoniae pneumonia appeared to be reliable when
found with the combination of bronchial wall thickening
and centrilobular nodules in the CT findings.
The M. pneumoniae organism attaches to cilia through the
P1 protein and multiplies in the respiratory epithelial
layer [1]. Attachment to epithelial cilia is essential for M.
pneumoniae infection, through to progression and mani-
festation as bronchial wall thickening. Histopathologi-
cally, it is characterized by acute cellular bronchiolitis
with edematous and ulcerative lesions of the bronchial
walls and by peribronchial and perivascular interstitial
opacities containing lymphocytes, plasma cells, and mac-
rophages [21-23]. In contrast, S. pneumoniae may not have
this biological capacity to directly infect the alveolar
lumen, thereby allowing pneumonia to progress [24].
Although S. pneumoniae can occasionally damage the res-
piratory epithelium directly, it rarely produces ongoing
disease in segmental bronchi. The main site of inflamma-
tion may reflect the CT findings.
Pneumonia due to M. pneumoniae is usually mild, but
some cases are known to develop into severe, life-threat-
ening pneumonia with respiratory failure and acute respi-
ratory distress syndrome [18,25,26]. This study compared
the CT findings between the early stage (mild to moderate
severity) and progressed stage (severe pneumonia with
respiratory failure) of M. pneumoniae pneumonia. Unfor-
tunately, all patients with progressed pneumonia did not
show the typical radiographic features of M. pneumoniae
pneumonia. For further evaluation of CT findings at the
progressed stage, 13 severe M. pneumoniae pneumonia
with respiratory failure were evaluated that were described
in a previous report [18]. These severe cases showed the
same CT findings of the above progressed cases and could
not be differentiated from S. pneumoniae pneumonia.
The limitation of the present study is the lack of inclusion
of pneumonia due to other common microorganisms
such as C. pneumoniae or Haemophilus influenzae. Because
C. pneumoniae pneumonia is usually mild and self-limit-
ing, it is treated in an outpatient setting without CT scan-
ning [3]. H. influenzae is usually detected from patients
with chronic lung diseases such as bronchiectasis, diffuse
panbronchiolitis, or chronic obstructive pulmonary dis-
ease. Thus, it is difficult to evaluate the precise CT findings
in H. influenzae pneumonia. Another limitation of the
present study is that it excluded patients with chronic lung
diseases and severe pneumonia for the precise evaluation
of CT findings. These diseases could influence CT find-
ings. In addition, M. pneumoniae usually infects young
adults with no or mild co-morbid illnesses [16,18,19]. A
further weakness of this study is its retrospective design
and small sample size, which are characteristic of such
preliminary studies. Thus, further studies are necessary to
determine whether CT findings could differentiate the var-
ious microorganisms with or without chronic lung dis-
eases. However, the usefulness of CT findings is limited to
hospitals with CT scanners. The guidelines are aimed at
general practitioners and non-specialized doctors and
were selected to allow easy differentiation of CAP in an
outpatient setting without special examinations [4]. Thus,
the JRS guidelines may not recommend the utilization of
chest CT routinely.
Conclusion
The main purpose of the present study was to identify a
means of rapidly distinguishing M. pneumoniae pneumo-
nia from S. pneumoniae pneumonia in daily clinical prac-
tice without waiting for serological results. The results
indicate that the combination of bronchial wall thicken-
ing and centrilobular nodules on chest CT is most sugges-
tive of M. pneumoniae pneumonia. The presence of
bilateral bronchial wall thickening or centrilobular nod-
ules was highly suggestive of M. pneumoniae pneumonia.
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